[ad_1]
The presentations highlighted the direct effect of NO on Mycobacterium abscessus (M. abscessus) and Pseudomonas aeruginosa (P. aeruginosa) as well as the use of the NO generator and system. administration as a potential treatment for the M. abscessus complex (MABSC GARDEN CITY, NY, and REHOVOT, Israel, July 16, 2018 (GLOBE NEWSWIRE) – AIT Therapeutics, Inc. (OTC: AITB), a medical device and biopharmaceutical company in Canada. Clinical stage focused on inhalation development The nitric oxide (NO) for the treatment of patients with respiratory diseases, including severe pulmonary infections and pulmonary hypertension, announced today that the in vitro data, as well as data from its compbadionate use study, were presented at 3 ] Annual World Bronchectasis Conference held at Georgetown University in Washington on July 12 and 14 llet 2018.
The first poster entitled: " High dose inhaled nitric oxide as a potential therapy against mycobacterium abscessus The pulmonary infection in cystic fibrosis " shows a in vitro response to the NO dose in the death of M. abscessuss as a monotherapy in sputum. It also shows differences in the minimal bactericidal concentration of NO between various clinical strains of M. abscessus in vitro. The results also revealed the susceptibility of P. aeruginosa to NO is significantly greater with a timeout less than half that observed with M. abscessus, and at a lower concentration.
The second poster, titled: " Treatment of Mycobacterium refractory refractory pulmonary infection with intermittent inhaled nitric oxide ," inhaled NO shows dosed at 160 parts per million (ppm ) for 30 minutes five times a day for 14 days and three times a day for 7 days provided clinical improvement on several parameters, including the 6-minute walking distance, FEV 1, and quality of life parameters that persisted up to 10 minutes. 90 days after stopping treatment. There was no effect on the bacterial load. This patient had underlying cystic fibrosis and the MABSC had persisted for more than 8 years.
Both posters can be viewed on the company's website at www.AIT-PHARM.com
"Results of processing with our NO generator and delivery system were consistent with the results shown from our NTM's study of nine patients recently using cylinder gas, "said Steven Lisi, president and chief executive officer of AIT Therapeutics. "We continue to be on track to begin a pivotal study by the end of 2019 on nontuberculous mycobacteria (NTMs) pending appropriate funding and we anticipate that this study will be conducted substantially in the context of Our in vitro data suggest that not only did M. abscessus be killed, but he more easily killed P. aeruginosa which is more widespread and with well-established pathogenicity. "
Andrew Colin, MD, director, Division of Pediatric Respirology at the University of Miami, said: "Confirmation of the destructive effect of nitric oxide in vitro on M. abscessus It is instructive to add to the death of Pseudomonas aeruginosa a notoriously harmful pathogen in our cystic fibrosis population, and we can begin to hope that NO could be the non-antibiotic antimicrobial we are The NTM community is anxiously awaiting the next step in the process with the NO generator and the delivery system. "
About Mycobacterium abscessus complex (MABSC) of the lungs
MABSC is the most aggressive and difficult species to treat non-tuberculous mycobacteria (NCDs) ). There is currently no approved treatment for MABSC. The current standard of care is a badtail of antibiotics that often turns out to be ineffective with serious side effects. Most patients with MABSC have an underlying condition, such as cystic fibrosis or chronic obstructive pulmonary disease (COPD). The median survival of those who suffer from MABSC is less than 5 years.
About Nitric Oxide (NO)
Nitric Oxide (NO) is a potent molecule that plays a critical role in a wide range of biological functions. In the airways, it is thought that NO plays a key role in the innate immune system at concentrations of about 200 ppm. In vitro studies suggest that NO has antimicrobial activity not only against common bacteria, both Gram-positive and Gram-negative, but also against other various organisms, including mycobacteria, fungi, yeasts and parasites, and has the potential to eliminate multi-drugs. resistant strains.
About the 3 Annual Bronchectasis Conference
The conference is a focused, state-of-the-art gathering of world experts on bronchiectasis and non-tuberculous mycobacterial lung infections. Highlights of the conference include presentations of the most recent research on the mechanisms of disease in bronchiectasis, including new understandings about the role of inflammation, infection, and the microbiome. Clinical topics will include sessions on the diagnosis and treatment of bronchiectasis and NCD infections, including small group presentations, specifically aimed at understanding the role of airway clearance, anti-inflammatory treatments and antibiotics.
AIT Therapeutics Inc. 19659014] AIT Therapeutics Inc. is a manufacturer of clinical-stage medical devices and biopharmaceuticals that uses nitric oxide (NO) to treat respiratory and other diseases. The Company currently uses its therapeutic expertise to treat lower respiratory tract infections that are not effectively treated with current standards of care, as well as pulmonary hypertension, in a variety of settings. AIT Therapeutics is currently advancing its revolutionary NO generation and delivery system in clinical trials for the treatment of bronchiolitis and severe pulmonary infections such as nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com
Forward-Looking Statement
This press release contains "forward-looking statements". Forward-looking statements include statements about our expectations, beliefs or intentions regarding our product offerings, business, financial condition, results of operations, strategies or prospects. You can identify these forward-looking statements by the words "plans", "plans", "plans", "plans", "believes", "estimates", "probable", "targets", "badumes", "targets" and similar expressions and / or the use of future temporal or conditional constructions (such as "will", "may", "could", "should" and others) and by the fact that these statements do not relate strictly to current issues. Forward-looking statements relate to events, activities, trends or results expected or expected as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, such statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from future results expressed or implied by forward-looking statements. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance. There are many factors that could cause our business or actual results to differ materially from the business and results anticipated in the forward-looking statements, including risks badociated with: our approach to discovering and developing new drugs that have never been proved; our funding capacity and the results of new preclinical and clinical trials; obtain, maintain and protect the intellectual property used by our products; our ability to enforce our patents against counterfeiters and defend our patent portfolio against third-party challenges; our ability to obtain additional funds to support our business activities; our reliance on third parties for the development, manufacture, marketing, sale and distribution of products; the successful development of our product candidates, which are in the early stages of development; obtain regulatory approval for products; competition from others by using technology similar to ours and others developing products for similar uses; our dependence on employees; and our short-term operating history. We badume no obligation to update, and we have no policy to update or revise these forward-looking statements except as required by applicable law.
CONTACT
Steven Lisi, Chief Executive Officer
AIT Therapeutics, Inc.
[email protected]
Bob Yedid
LifeSci Consultants, LLC
Bob @ LifeSciAdvisors. com
(646) 597-698
Source link
